Mario A Eisenberger

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. pmc The experience with cytotoxic chemotherapy in metastatic castration-resistant prostate cancer
    Mario A Eisenberger
    Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University, Baltimore, MD, USA
    Urol Clin North Am 39:573-81. 2012
  2. pmc CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer
    Patrick J Bastian
    James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    J Urol 179:529-34; discussion 534-5. 2008
  3. ncbi Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy
    Gopal K Bajaj
    Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Urology 69:526-31. 2007
  4. pmc An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy
    Emmanuel S Antonarakis
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Cancer 118:6063-71. 2012
  5. pmc The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen deprivation
    Daniel Keizman
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland 21231, USA
    Prostate 71:1608-15. 2011
  6. pmc The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up
    Emmanuel S Antonarakis
    Prostate Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center, Brady Urological Institute, Johns Hopkins University, Baltimore, MD 21231, USA
    BJU Int 109:32-9. 2012
  7. ncbi Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy
    Eli Rosenbaum
    Department of Otolaryngology Head and Neck Surgery, Head and Neck Cancer Research Division, John Hopkins School of Medicine, Baltimore, MD 21205 2196, USA
    Clin Cancer Res 11:8321-5. 2005
  8. pmc The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma
    Daniel Keizman
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Eur J Cancer 48:202-8. 2012
  9. pmc The effect of clinical trial participation versus non-participation on overall survival in men receiving first-line docetaxel-containing chemotherapy for metastatic castration-resistant prostate cancer
    Jatinder Goyal
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University, Baltimore, MD 21231, USA
    BJU Int 110:E575-82. 2012
  10. ncbi Effect of bisphosphonates (Bis) combined with sunitinib (Su) on the response rate (RR), progression-free survival (PFS), and overall survival (OS) of patients (pts) with bone metastases (mets) from renal cell carcinoma (RCC)
    Daniel Keizman
    Genitourinary Oncology Service, Division of Oncology, Meir Medical Center, Sackler School of Medicine, Tel Aviv University, Kfar Saba, Israel Annapolis Oncology Center, Annapolis, MD Roswell Park Cancer Institute, Buffalo, NY Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD The Johns Hopkins Medical Institutions, Baltimore, MD Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel Uro oncologist, Tel Hashomer, Tel Hashomer, Israel Department of Oncology, Wolfson Medical Center, Holon, Israel Rambam Health Care Campus, Haifa, Israel Department of Oncology, Asaf Harofe Medical Center, Zerifin, Israel Assaf Harofeh Medical Center, Zerifin, Israel
    J Clin Oncol 30:379. 2012

Collaborators

Detail Information

Publications51

  1. pmc The experience with cytotoxic chemotherapy in metastatic castration-resistant prostate cancer
    Mario A Eisenberger
    Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University, Baltimore, MD, USA
    Urol Clin North Am 39:573-81. 2012
    ..These data are intended to provide physicians and patients with a general idea on the outcomes of men with mCRPC that may facilitate clinical decisions as well as the design and evaluation of clinical trials...
  2. pmc CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer
    Patrick J Bastian
    James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    J Urol 179:529-34; discussion 534-5. 2008
    ..In this study we investigated the hypermethylation profile of several genes in the serum of men with localized and hormone refractory prostate cancer...
  3. ncbi Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy
    Gopal K Bajaj
    Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Urology 69:526-31. 2007
    ..This Phase II study was undertaken to determine the safety and efficacy of imatinib mesylate in men with biochemical relapse of nonmetastatic, androgen-sensitive prostate cancer after local therapy...
  4. pmc An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy
    Emmanuel S Antonarakis
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Cancer 118:6063-71. 2012
    ..The authors examined PTEN and additional protein markers in primary tumors from patients with high-risk, localized prostate cancer who received adjuvant docetaxel in a prospective multicenter trial (TAX2501)...
  5. pmc The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen deprivation
    Daniel Keizman
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland 21231, USA
    Prostate 71:1608-15. 2011
    ..We sought to determine the change of PSA doubling time (PSADT) and its association with disease progression during intermittent androgen deprivation (IAD) therapy for prostate cancer...
  6. pmc The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up
    Emmanuel S Antonarakis
    Prostate Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center, Brady Urological Institute, Johns Hopkins University, Baltimore, MD 21231, USA
    BJU Int 109:32-9. 2012
    ..To describe metastasis-free survival (MFS) in men with prostate-specific antigen (PSA) recurrence following radical prostatectomy, and to define clinical prognostic factors modifying metastatic risk...
  7. ncbi Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy
    Eli Rosenbaum
    Department of Otolaryngology Head and Neck Surgery, Head and Neck Cancer Research Division, John Hopkins School of Medicine, Baltimore, MD 21205 2196, USA
    Clin Cancer Res 11:8321-5. 2005
    ..To analyze the prognostic significance of six epigenetic biomarkers (APC, Cyclin D2, GSTP1, TIG1, Rassf1A, and RARbeta2 promoter hypermethylation) in a homogeneous group of prostate cancer patients, following radical prostatectomy alone...
  8. pmc The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma
    Daniel Keizman
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Eur J Cancer 48:202-8. 2012
    ..Sunitinib is a standard treatment for metastatic renal cell carcinoma (mRCC). The neutrophil to lymphocyte ratio (NLR), an index of systemic inflammation, is associated with outcome in several cancer types...
  9. pmc The effect of clinical trial participation versus non-participation on overall survival in men receiving first-line docetaxel-containing chemotherapy for metastatic castration-resistant prostate cancer
    Jatinder Goyal
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University, Baltimore, MD 21231, USA
    BJU Int 110:E575-82. 2012
    ..After accounting for potential baseline inequalities, participation in a clinical trial itself was associated with significantly longer overall survival in these patients...
  10. ncbi Effect of bisphosphonates (Bis) combined with sunitinib (Su) on the response rate (RR), progression-free survival (PFS), and overall survival (OS) of patients (pts) with bone metastases (mets) from renal cell carcinoma (RCC)
    Daniel Keizman
    Genitourinary Oncology Service, Division of Oncology, Meir Medical Center, Sackler School of Medicine, Tel Aviv University, Kfar Saba, Israel Annapolis Oncology Center, Annapolis, MD Roswell Park Cancer Institute, Buffalo, NY Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD The Johns Hopkins Medical Institutions, Baltimore, MD Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel Uro oncologist, Tel Hashomer, Tel Hashomer, Israel Department of Oncology, Wolfson Medical Center, Holon, Israel Rambam Health Care Campus, Haifa, Israel Department of Oncology, Asaf Harofe Medical Center, Zerifin, Israel Assaf Harofeh Medical Center, Zerifin, Israel
    J Clin Oncol 30:379. 2012
    ..379 Background: Bis are used to prevent skeletal events of bone mets, and may exhibit anti tumor effects. We aimed to evaluate whether Bis can bring a RR, PFS, and OS benefit to pts with bone mets from RCC that are treated with Su...
  11. ncbi Marimastat in the treatment of patients with biochemically relapsed prostate cancer: a prospective randomized, double-blind, phase I/II trial
    Eli Rosenbaum
    Department of Radiation Oncology and Molecular Sciences, Division of Medical Oncology and Biostatistics and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Clin Cancer Res 11:4437-43. 2005
    ..To evaluate the safety and biological activity of three different doses of marimastat given for 6 months to patients with biochemically relapsed prostate cancer...
  12. ncbi Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma
    Victoria J Sinibaldi
    Prostate Cancer Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Am J Clin Oncol 29:395-8. 2006
    ....
  13. pmc AIM1 promoter hypermethylation as a predictor of decreased risk of recurrence following radical prostatectomy
    Eli Rosenbaum
    Department of Otolaryngology and Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Prostate 72:1133-9. 2012
    ..To evaluate the prognostic significance of six epigenetic biomarkers (AIM1, CDH1, KIF1A, MT1G, PAK3, and RBM6 promoter hypermethlation) in a homogeneous group of prostate cancer patients, following radical prostatectomy (RP)...
  14. doi A Retrospective Analysis of the Effect on Survival of Time from Diagnosis to Neoadjuvant Chemotherapy to Cystectomy for Muscle Invasive Bladder Cancer
    Jong Chul Park
    Department of Oncology, Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
    J Urol 195:880-5. 2016
    ..We determine the impact of the timing of radical cystectomy from the diagnosis of muscle invasive bladder cancer on survival in patients also treated with neoadjuvant chemotherapy...
  15. pmc Contemporary experience with ketoconazole in patients with metastatic castration-resistant prostate cancer: clinical factors associated with PSA response and disease progression
    Daniel Keizman
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
    Prostate 72:461-7. 2012
    ....
  16. pmc The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy
    Danil V Makarov
    James Buchanan Brady Urological Institute and the Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    J Urol 179:156-61; discussion 161-2. 2008
    ....
  17. pmc Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint
    Connie Collins
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Cancer Biol Ther 6:1360-7. 2007
    ..CEP-701 binds to serum proteins and a preprostatectomy study was performed to assess prostate tissue penetration and clinical response to CEP-701...
  18. pmc Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial
    Emmanuel S Antonarakis
    Prostate Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, CRB1 1M59, 1650 Orleans Street, Baltimore, MD 21231, USA
    Cancer Chemother Pharmacol 69:763-71. 2012
    ..However, because of differences in antibody-dependent cellular cytotoxicity between AGS-PSCA and AGS-1C4D4, a limited Phase I trial using AGS-1C4D4 was performed evaluating safety and PK...
  19. pmc Phase I trial with a combination of docetaxel and ¹⁵³Sm-lexidronam in patients with castration-resistant metastatic prostate cancer
    Jianqing Lin
    Prostate Cancer Program, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA
    Urol Oncol 29:670-5. 2011
    ....
  20. pmc A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone
    Lee P Resta
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, CRB1 1M59, Baltimore, MD 21231, USA
    Cancer Chemother Pharmacol 67:431-8. 2011
    ..To find the maximum tolerated dose (MTD) of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors...
  21. pmc Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer
    Daniel J Zabransky
    Johns Hopkins Kimmel Cancer Center, Johns Hopkins University, Baltimore, MD, USA
    Prostate 72:487-98. 2012
    ....
  22. doi Outcomes of patients after aborted radical cystectomy for intraoperative findings of metastatic disease
    Thomas J Guzzo
    The Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, MD 21287 2101, USA
    BJU Int 102:1539-43. 2008
    ....
  23. ncbi Overall survival of men with metastatic castration-resistant prostate cancer (mCRPC) receiving first-line docetaxel-containing chemotherapy according to their participation (or not) in clinical trials
    Jatinder Goyal
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD Brady Urological Institute at Johns Hopkins University School of Medicine, Baltimore, MD
    J Clin Oncol 30:148. 2012
    ..We compared clinical characteristics and survival outcomes of patients with mCRPC receiving first-line docetaxel-containing therapy on a clinical study (trial participants) or outside of a clinical trial (non-participants)...
  24. pmc Management of patients with biochemical recurrence after local therapy for prostate cancer
    Channing J Paller
    Prostate Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, CRB1 1M59, Baltimore, MD 21287, USA
    Hematol Oncol Clin North Am 27:1205-19, viii. 2013
    ..A risk-stratified approach informed by the patient's prostate-specific antigen kinetics, comorbidities, and personal preferences is recommended to determine the best management approach. ..
  25. pmc Survival in men with nonmetastatic prostate cancer treated with hormone therapy: a quantitative systematic review
    Emmanuel S Antonarakis
    Prostate Cancer Research Program, and the Division of Oncology Biostatistics, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA
    J Clin Oncol 25:4998-5008. 2007
    ....
  26. pmc Changes in PSA kinetics predict metastasis- free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents: combined analysis of 4 phase II trials
    Emmanuel S Antonarakis
    Prostate Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, CRB1 1M45, 1650 Orleans Street, Baltimore, MD 21231, USA
    Cancer 118:1533-42. 2012
    ..However, it is unknown whether changes in PSA kinetics influence metastasis-free survival (MFS)...
  27. pmc Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination
    Daniel Keizman
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Eur J Cancer 47:1955-61. 2011
    ..Data suggests that they may inhibit tumourigenesis...
  28. ncbi Clinical practice. Localized prostate cancer
    Patrick C Walsh
    James Buchanan Brady Urological Institute, The Sidney Kimmel Comprehensive Cancer Center, The Department of Urology, Radiation Oncology and Molecular Radiation Sciences, and Johns Hopkins Medical Institutions, Baltimore, MD 21287 2101, USA
    N Engl J Med 357:2696-705. 2007
  29. ncbi Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy
    Patrick J Bastian
    The James Buchanan Brady Urological Institute and Department of Urology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231 1000, USA
    Clin Cancer Res 11:4037-43. 2005
    ..We evaluated circulating cell-free DNA GSTP1 CpG island hypermethylation as a prognostic biomarker in the serum of men with prostate cancer...
  30. ncbi Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible mechanism of action
    Mario A Eisenberger
    Johns Hopkins Medical Institutions, Baltimore, Maryland 21231 1000, USA
    Urology 63:114-9. 2004
    ..To study the safety, pharmacokinetics, biologic activity, and preliminary efficacy of the bispecific 5-alpha-reductase inhibitor (LY320236) in prostate cancer...
  31. ncbi Influence of risk factors for renal cell carcinoma (RCC) on outcome of patients (pts) with metastatic disease treated with sunitinib
    Daniel Keizman
    Genitourinary Oncology Service, Division of Oncology, Meir Medical Center, Sackler School of Medicine, Tel Aviv University, Kfar Saba, Israel Annapolis Oncology Center, Annapolis, MD Roswell Park Cancer Institute, Buffalo, NY Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD The Johns Hopkins Medical Institutions, Baltimore, MD Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel Uro oncologist, Tel Hashomer, Tel Hashomer, Israel Department of Oncology, Wolfson Medical Center, Holon, Israel Rambam Health Care Campus, Haifa, Israel Department of Oncology, Asaf Harofe Medical Center, Zerifin, Israel Assaf Harofeh Medical Center, Zerifin, Israel
    J Clin Oncol 30:437. 2012
    ..Their presence has been associated with a worse outcome of therapy (tx) in various metastatic cancers. We sought to determine their influence on the progression free survival (PFS) and overall survival (OS) of Su tx in mRCC...
  32. doi Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies
    Rosa Nadal
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland
    Prostate 76:512-20. 2016
    ....
  33. pmc Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
    Emmanuel S Antonarakis
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland
    JAMA Oncol 1:582-91. 2015
    ....
  34. pmc Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study
    Michael T Schweizer
    The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Sci Transl Med 7:269ra2. 2015
    ..BAT shows promise as treatment for CRPC and should be further evaluated in larger trials. ..
  35. pmc Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel
    Philipp Nuhn
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University, Baltimore, MD, USA Department of Urology, Ludwig Maximilians Universitat, Munich, Germany
    BJU Int 114:E11-7. 2014
    ....
  36. pmc Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database
    Emmanuel S Antonarakis
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    BJU Int 108:378-85. 2011
    ....
  37. ncbi Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics
    Michael A Carducci
    Division of Medical Oncology, The Johns Hopkins Oncology Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
    J Clin Oncol 20:2171-80. 2002
    ..Atrasentan, an endothelin antagonist, binds selectively to the ET(A) receptor. This study evaluated the safety, pharmacokinetics, and maximum-tolerated dose of atrasentan in cancer patients...
  38. pmc Sarcomatoid Carcinoma of the Prostate: Retrospective Review of a Case Series From the Johns Hopkins Hospital
    Mark C Markowski
    Division of Medical Oncology, Sidney Kimmel Cancer Center, The Johns Hopkins University, Baltimore, MD
    Urology 86:539-43. 2015
    ..To identify survival differences in patients with sarcomatoid prostate cancer based on initial staging and treatment regimens...
  39. pmc Is abiraterone acetate well tolerated and effective in the treatment of castration-resistant prostate cancer?
    Emmanuel S Antonarakis
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins School of Medicine, 1650 Orleans Street, Baltimore, MD 21231, USA
    Nat Clin Pract Oncol 6:12-3. 2009
    ..Multi-institutional, prospective trials should provide additional information on the tolerability and activity of this compound and further define the population most likely to benefit from this endocrine approach...
  40. ncbi The role of cytotoxic chemotherapy in prostate cancer. A critical reevaluation 20 years later
    Mario A Eisenberger
    The Johns Hopkins University, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231 1000, USA
    Oncology (Williston Park) 20:853-62; discussion 863, 867-8. 2006
    ....
  41. ncbi Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma
    Victoria J Sinibaldi
    Department of Oncology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21205, USA
    Cancer 94:1457-65. 2002
    ..To preserve the therapeutic synergism between docetaxel and EMP, they designed a regimen employing higher doses of oral EMP administered on the day of the docetaxel infusion...
  42. ncbi Pretreatment (pre-tx) neutrophil to lymphocyte ratio (NLR) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with ketoconazole (keto): Association with outcome and predictive model
    Daniel Keizman
    Genitourinary Oncology Service, Division of Oncology, Meir Medical Center, Sackler School of Medicine, Tel Aviv University, Kfar Saba, Israel Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD The Johns Hopkins Medical Institutions, Baltimore, MD Assaf Harofeh Medical Center, Zerifin, Israel
    J Clin Oncol 30:37. 2012
    ..The NLR, an index of systemic inflammation, is associated with prognosis in several types of cancer. We assessed the association between pre-tx NLR and outcome of mCRPC pts treated with keto...
  43. pmc Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer
    Zsolt Szabo
    The Russell H Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Cancer Research Bldg 2, Room 492, 1550 Orleans St, Baltimore, MD, 21231, USA
    Mol Imaging Biol 17:565-74. 2015
    ..Here we present initial safety, biodistribution, and radiation dosimetry results with [(18)F]DCFPyL, a second-generation fluorine-18-labeled small-molecule PSMA inhibitor, in patients with prostate cancer...
  44. pmc The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer
    Michael T Schweizer
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Eur Urol 66:646-52. 2014
    ..This raises the possibility of cross-resistance between androgen-directed agents and docetaxel...
  45. doi Evolving new treatments for patients with prostate cancer: the advanced disease paradigm of the PSA era
    Mario A Eisenberger
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Urol Oncol 26:406-7. 2008
  46. ncbi Therapeutic considerations for patients with high-risk, nonmetastatic, prostate cancer
    Mario A Eisenberger
    Department of Oncology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Semin Urol Oncol 20:19-23. 2002
    ..Genotypic and phenotypic characterization of patients in clinical trials may enhance future therapeutic prospects in this disease...
  47. ncbi The dilemma of patients with a rising PSA level after definitive local therapy for prostate cancer
    Lance K Lassiter
    Division of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Semin Urol Oncol 20:146-54. 2002
    ....
  48. pmc Small cell carcinoma of the prostate
    Rosa Nadal
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 1650 Orleans Street, Baltimore, MD 21231 1000, USA
    Nat Rev Urol 11:213-9. 2014
    ..Chemotherapy is the standard approach for treating patients with either localized or advanced prostatic SCC. Despite the emergence of more-aggressive treatment modalities, the prognosis of men with prostatic SCC remains dismal. ..
  49. pmc Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer
    Steve Y Cho
    Russell H Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, Maryland 21287 0014, USA
    J Nucl Med 53:1883-91. 2012
    ..Here, we describe the initial clinical experience and radiation dosimetry of (18)F-DCFBC in men with metastatic PCa...
  50. pmc Does short-term ADT before and during radiation therapy improve outcomes in locally advanced prostate cancer?
    Emmanuel S Antonarakis
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD 21231, USA
    Nat Clin Pract Urol 5:480-1. 2008
    ....
  51. ncbi Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study
    Menachem Laufer
    Department of Urology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, MD, USA
    J Clin Oncol 21:697-703. 2003
    ..To determine maximum-tolerated dose, toxicities, and pharmacokinetics associated with weekly intravesical gemcitabine therapy in patients with superficial bladder cancer...